Discover the top 5 regulatory biosimilar news of 2025, highlighting FDA approvals that enhance treatment options and ...
Tyruko, the first natalizumab biosimilar for multiple sclerosis, promises significant savings and competition in the US market.
Biosimilar developers achieve key European approvals for denosumab and golimumab, enhancing patient access while facing US market entry delays.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback